GLUD1 and cancer: Inhibiting GLUD1/RSK2 has been shown to enhance the infiltration of CD8 + T cells and increase IFN-γ levels within tumors, indicating the critical role of GLUD1 in shaping the immune microenvironment in specific cancer subtypes [207].